DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard
By integrating Rockwell Automation’s FactoryTalk Optix, NKP Pharma has achieved compliance with USFDA 21 CFR Part 11
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Strengthening capabilities in Peptide Therapeutics and CDMO services
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
Subscribe To Our Newsletter & Stay Updated
